USD 1.05
(-1.87%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -8.52 Million USD | -20.97% |
2022 | -7.04 Million USD | -227.48% |
2021 | -2.15 Million USD | -3082.26% |
2020 | -67.63 Thousand USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -1.76 Million USD | 42.15% |
2024 Q2 | -1.73 Million USD | 2.12% |
2023 Q1 | -1.33 Million USD | 0.62% |
2023 Q3 | -3.16 Million USD | -225.71% |
2023 FY | -8.52 Million USD | -20.97% |
2023 Q4 | -3.05 Million USD | 3.28% |
2023 Q2 | -970.22 Thousand USD | 27.56% |
2022 Q3 | -1.8 Million USD | 25.29% |
2022 FY | -7.04 Million USD | -227.48% |
2022 Q1 | -1.47 Million USD | 0.0% |
2022 Q4 | -1.34 Million USD | 25.47% |
2022 Q2 | -2.42 Million USD | -64.54% |
2021 Q1 | -52.05 Thousand USD | 0.0% |
2021 FY | -2.15 Million USD | -3082.26% |
2020 FY | -67.63 Thousand USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Amgen Inc. | 7.89 Billion USD | 100.108% |
AstraZeneca PLC | 8.19 Billion USD | 100.104% |
Biogen Inc. | 1.29 Billion USD | 100.657% |
Gilead Sciences, Inc. | 7.6 Billion USD | 100.112% |
Scilex Holding Company | -105.43 Million USD | 91.913% |
Scilex Holding Company | -105.43 Million USD | 91.913% |